CHICAGO, Dec. 1, 2021 /PRNewswire/ — ARCH Venture Partners, one of many world’s main early-stage expertise enterprise companies, in the present day introduced new Enterprise Companions, together with John Maraganore, Ph.D., Jake Bauer, Luciana Borio, M.D., Axel Bouchon, Ph.D., and Sabah Oney, Ph.D. The agency additional acknowledged a number of new hires and promotions, together with the elevation of Carol Suh to Accomplice.
“Earlier this yr we introduced our largest fund thus far, which is a mirrored image of confidence within the abilities and experience we deliver to bear, not simply from an funding perspective but additionally by way of figuring out easy methods to construct nice firms. We’re firm builders and buyers and sit up for constructing nice and excessive affect firms with our new colleagues,” stated Managing Director Kristina Burow.
“Individuals come to ARCH to make an affect and to forestall and remedy ailments. We’re honored to have such a artistic and achieved group be part of the group,” stated ARCH Co-founder and Managing Director Robert Nelsen.
The Enterprise Companions introduced in the present day signify a wide selection of perspective and expertise on the highest ranges of biotechnology and life science organizations. John Maraganore is the founding CEO of Alnylam Prescribed drugs. Jake Bauer is a biotech govt with a confirmed observe report in firm formation, technique, management, and company and enterprise growth, most not too long ago as Chief Enterprise Officer of MyoKardia. Luciana Borio brings intensive expertise in authorities, biodefense, public well being and medical innovation. Axel Bouchon is concentrated on neuroscience and the prevention of neurological ailments. Sabah Oney is an skilled biotech govt, most not too long ago as Chief Enterprise Officer of Alector.
“I used to be drawn to ARCH due to its deep involvement in serving to firms harness breakthrough applied sciences to have a direct constructive affect on folks’s lives. It’s a privilege to be becoming a member of a group that’s famend for this relentless focus,” stated John Maraganore, Ph.D.
“I’m excited to be on the group at ARCH as a result of this can be a place the place enterprise is a group sport. We worth one another as people and harness the vary of experience every individual brings to the desk. Founders and their firms profit from the varied abilities and expertise represented on our group,” stated Luciana Borio, M.D.
Along with naming new Enterprise Companions, the agency acknowledged the promotion of Carol Suh to Accomplice. Suh performed a pivotal position in founding the not too long ago launched neuroscience firm, Neumora, and helped launch Sana Biotechnology and Boundless Bio. She has been acknowledged beforehand as a rising star by Forbes’ 30 below 30 and Endpoints Information’ 20 Beneath 40 lists.
Different key additions to the ARCH group embrace:
- Zachary Wensch as Senior Vice President of Finance
- Jay Kocherlakota and Su Fu as Senior Associates
- Inca Dieterich, Ph.D., and Peter Mintun as Associates
- Carrie Helland as an Entrepreneur-In-Residence
In January, the agency raised over $1.85 billion in ARCH Enterprise Fund XI to put money into early-stage biotechnology firms engaged on infectious illness, psychological well being, immunology, oncology, neurology, manufacturing, scientific trials, anti-aging medicines, genomic and organic instruments, information sciences, and methods of reimagining diagnostics and therapies.
Enterprise Accomplice and Accomplice Biographies
Dr. John Maraganore is the founding CEO of Alnylam Prescribed drugs, the place he is introduced his deliberate departure at yr finish. At Alnylam, he led the development of RNAi therapeutics as an entire new class of medicines, bringing 4 accepted medicines (ONPATTROTM, GIVLAARITM, OXLUMOTM, and LeqvioTM) to sufferers world wide. Previous to Alnylam, Dr. Maraganore served as an officer and a member of the administration group for Millennium Prescribed drugs, Inc., the place he led the corporate’s product franchise, strategic planning and M&A, and biotherapeutic features. Earlier than Millennium, he served as Director of Molecular Biology and Director of Market and Enterprise Improvement at Biogen, Inc. At Biogen, he additionally invented and led the invention and growth of ANGIOMAX® (bivalirudin) for injection. Previous to Biogen, he was a scientist at ZymoGenetics, Inc., and the Upjohn Firm.
Dr. Maraganore acquired his Grasp of Science and Ph.D. in biochemistry and molecular biology on the College of Chicago. He’s a member of the Board for Agios Prescribed drugs, Beam Therapeutics, and the Biotechnology Business Group (BIO).
Jake Bauer is a biotech govt and chief within the biopharmaceutical trade with a confirmed observe report in firm formation, technique, govt and undertaking management, and company and enterprise growth. Previous to MyoKardia Inc.’s acquisition by Bristol Myers Squibb in November 2020, he served because the Chief Enterprise Officer of MyoKardia. Previous to this, he served as Senior Vice President, Finance and Company Improvement and Principal Monetary Officer of MyoKardia having joined the corporate in 2014. In earlier roles, Bauer served as Vice President, Enterprise Operations and head of company growth at Ablexis, LLC and as a principal at Third Rock Ventures. Whereas at Third Rock Ventures, he was actively concerned in a wide range of main biopharmaceutical firms together with Agios Prescribed drugs, Inc., CytomX Therapeutics Inc., and World Blood Therapeutics, Inc. Beforehand, he served in roles within the funding group at Royalty Pharma, the enterprise growth group at Endo Prescribed drugs Inc. and as a administration marketing consultant at Putnam Associates.
Bauer holds a B.S. in biology and a B.A. in economics from Duke College and an M.B.A. from Harvard Enterprise Faculty. He at the moment serves on the boards of Attralus, Enliven Therapeutics, Phoenix Tissue Restore, Inc., and Arya Sciences Acquisition Corp V.
Dr. Luciana Borio advises on and helps develop new funding alternatives associated to biologics manufacturing, scientific trials, novel therapies and areas with giant unmet scientific wants. She is a specialist in biodefense, rising infectious ailments, medical product growth, and sophisticated public well being emergencies. Previous to becoming a member of ARCH, she was a senior vp at In-Q-Tel, an unbiased, non-profit, strategic funding agency that works to ship modern expertise options to assist the missions of the U.S. Intelligence Group. Previous positions embrace serving as a member of President Biden’s transition COVID-19 Advisory Board and Director for Medical and Biodefense Preparedness on the Nationwide Safety Council (2017-2019), the place she coordinated the response to the Ebola epidemic in West Africa, efforts to fight antimicrobial resistance, and the event of an Govt Order to modernize America’s influenza vaccines. Previous to that, she was the Performing Chief Scientist (2015-2017) and the Assistant Commissioner for Counterterrorism Coverage (2010-2017) on the U.S. Meals and Drug Administration.
Dr. Borio is an adjunct Assistant Professor of Medication at Johns Hopkins College (2003-present), the place she continues to observe medication part-time. She can be a senior fellow for international well being on the Council on Overseas Relations. Dr. Borio obtained her M.D. from George Washington College, accomplished a residency in inner medication at New York-Presbyterian/Weill Cornell Medical Middle, and a mixed fellowship in infectious ailments at Johns Hopkins and important care on the Nationwide Institutes of Well being. In 2021, she was elected to the Nationwide Academy of Medication.
Dr. Axel Bouchon is a biochemist, writer and serial entrepreneur within the biotech, client and expertise industries and is concentrated on neuroscience and prevention of neurological ailments. He’s basically pushed by the query “What makes our brains actually glad?”.
He’s a Director at Brii Biosciences, Co-founder and Chairman of BrainLuxury, Inc., and Co-founder and CEO of BrainGames Company. Earlier than becoming a member of ARCH, Dr. Bouchon was main the enterprise actions of LEAPS by Bayer (2015-2019) and Moderna Therapeutics, Inc. (2013-2014), and served as CEO, Director and Chairman in a number of pharmaceutical and biotechnology firms during the last 15 years.
Dr. Bouchon holds a Ph.D. in biochemistry, natural chemistry and immunology from the College of Tuebingen, Germany.
Dr. Sabah Oney focuses on the creation and growth of latest biotechnology firms. Previous to becoming a member of ARCH, Dr. Oney was the Chief Enterprise Officer of Alector, a biotech firm engaged on leveraging the immune system to find cures for neurodegenerative ailments. At Alector, he served as a member of the Govt Committee and performed a major position in firm’s development and guided the corporate via a number of milestones together with its IPO and a number of other main partnerships. Previous to Alector, Dr. Oney was at Ariosa Diagnostics, a biotechnology firm specializing in cell-free DNA based mostly non-invasive genetic testing the place he performed a pivotal position overseeing the worldwide growth of firm’s merchandise. Ariosa was acquired by Roche in 2015. Previous to that, Dr. Oney was a senior scientist at a biotechnology startup targeted on a systemic siRNA-delivery platform expertise.
Dr. Oney holds a B.S. diploma in Genetics from The College of Kansas the place he was a Fulbright Scholar, a Ph.D. in Genetics and Genomics from Duke College, and an M.B.A. from The Stanford College Graduate Faculty of Enterprise.
Carol Suh joined the corporate in 2018 as an Affiliate and was named Accomplice in 2021. Suh focuses on figuring out and evaluating new life science applied sciences and is concerned in firm creation. She is a stem cell biologist by coaching and combines her scientific experience with experiences on the enterprise facet of biotech. She helped construct Sana Biotechnology, Autobahn Therapeutics and Boundless Bio. Previous to ARCH, she helped launch Magenta Therapeutics, a biotech firm reworking the best way bone marrow stem cell transplants are carried out. Beforehand, she was a marketing consultant at Trinity Companions, working with a variety of biotech and pharma firms on company technique, market analysis, and enterprise growth. She started her profession in R&D Technique with GlaxoSmithKline’s Regenerative Medication group. For her work, she was acknowledged on the 2015 Forbes 30 Beneath 30 checklist in Healthcare.
Suh holds an A.B. in Molecular Mobile Biology from Harvard College, the place she skilled below Dr. David Scadden on the Harvard Stem Cell Institute. She additionally holds a M.Phil. from Yale College and was awarded the Nationwide Science Basis Graduate Analysis Fellowship for her work in stem cell biology. She accomplished her M.B.A. from Stanford Graduate Faculty of Enterprise.
About ARCH Enterprise Companions:
ARCH Enterprise Companions invests in superior expertise firms and is likely one of the world’s main early-stage expertise enterprise companies. The agency is a acknowledged chief in commercializing applied sciences developed at educational establishments, company analysis teams and nationwide laboratories. ARCH invests primarily in firms it co-founds with main scientists and entrepreneurs, bringing improvements in life sciences and bodily sciences to market.
For extra data, go to www.archventure.com.
Contact:
Morgan Warners
Finsbury Glover Hering
[email protected]
SOURCE ARCH Enterprise Companions
